Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2014 (2014), Article ID 231651, 6 pages
http://dx.doi.org/10.1155/2014/231651
Case Report

Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge

1Department of Internal Medicine, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USA
2Department of Endocrinology, Marshfield Clinic, Marshfield, WI 54449, USA

Received 16 September 2014; Accepted 23 October 2014; Published 12 November 2014

Academic Editor: Grigorios Korosoglou

Copyright © 2014 Umang Barvalia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K.-H. Yiu, M.-H. Jim, C.-W. Siu et al., “Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 1, pp. 109–114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. G. Julian, A. J. Camm, G. Frangin et al., “Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT,” The Lancet, vol. 349, no. 9053, pp. 667–674, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. C. M. Newman, A. Price, D. W. Davies, T. A. Gray, and A. P. Weetman, “Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy,” Heart, vol. 79, no. 2, pp. 121–127, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Aanderud, J. Sundsfjord, and J. Aarbakke, “Amiodarone inhibits the conversion of thyroxine to triiodothyronine in isolated rat hepatocytes,” Endocrinology, vol. 115, no. 4, pp. 1605–1608, 1984. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Safran, S.-L. Fang, G. Bambini, A. Pinchera, E. Martino, and L. E. Braverman, “Effects of amiodarone and desethylamiodarone on pituitary deiodinase activity and thyrotropin secretion in the rat,” American Journal of the Medical Sciences, vol. 292, no. 3, pp. 136–141, 1986. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Zaninovich, S. Bosco, and A. Fernandez-Pol, “Amiodarone does not affect the distribution and fractional turnover of triiodothyronine from the plasma pool, but only its generation from thyroxine in extrathyroidal tissues,” The Journal of Clinical Endocrinology & Metabolism, vol. 70, no. 6, pp. 1721–1724, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. E. P. Krenning, R. Docter, B. Bernard, T. Visser, and G. Hennemann, “Decreased transport of thyroxine (T4), 3,3′-5-triiodothyronine (T3) and 3,3′,5′-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs,” FEBS Letters, vol. 140, no. 2, pp. 229–233, 1982. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Martino, F. Aghini-Lombardi, S. Mariotti, L. Bartalena, L. Braverman, and A. Pinchera, “Amiodarone: a common source of iodine-induced thyrotoxicosis,” Hormone Research, vol. 26, no. 1–4, pp. 158–171, 1987. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Basaria and D. S. Cooper, “Amiodarone and the thyroid,” The American Journal of Medicine, vol. 118, no. 7, pp. 706–714, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Cohen-Lehman, P. Dahl, S. Danzi, and I. Klein, “Effects of amiodarone therapy on thyroid function,” Nature Reviews Endocrinology, vol. 6, no. 1, pp. 34–41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Tomisti, G. Rossi, L. Bartalena, E. Martino, and F. Bogazzi, “The onset time of amiodarone -induced thyrotoxicosis (AIT) depends on AIT type,” European Journal of Endocrinology, vol. 171, no. 3, Article ID 363368, pp. 363–368, 2014. View at Google Scholar
  12. F. Bogazzi, L. Bartalena, and E. Martino, “Approach to the patient with amiodarone-induced thyrotoxicosis,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2529–2535, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Bogazzi, E. Martino, E. Dell'Unto et al., “Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis,” Journal of Endocrinological Investigation, vol. 26, no. 7, pp. 635–640, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Bogazzi, L. Bartalena, S. Brogioni et al., “Color flow doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis,” Thyroid, vol. 7, no. 4, pp. 541–545, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Loy, E. Perra, A. Melis et al., “Color-flow doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis,” Acta Radiologica, vol. 48, no. 6, pp. 628–634, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Piga, M. C. Cocco, A. Serra, F. Boi, M. Loy, and S. Mariotti, “The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis,” European Journal of Endocrinology, vol. 159, no. 4, pp. 423–429, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Bartalena, S. Brogioni, L. Grasso et al., “Interleukin-6: a marker of thyroid-destructive processes?” Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 5, pp. 1424–1427, 1994. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Bartalena, S. Brogioni, L. Grasso, F. Bogazzi, A. Burelli, and E. Martino, “Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 8, pp. 2930–2933, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Bogazzi, L. Bartalena, L. Tomisti et al., “Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 556–562, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Bogazzi, L. Bartalena, L. Tomisti, G. Rossi, S. Brogioni, and E. Martino, “Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 11, pp. 3374–3380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Bogazzi, L. Bartalena, C. Cosci et al., “Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 1999–2002, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Bogazzi, L. Tomisti, G. Rossi et al., “Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 10, pp. 3757–3762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Guitierrez-Repiso, N. Colomo, G. Rojo-Martinez et al., “Evolution of urinary iodine excretion over eleven years in an adult population,” Clinical Nutrition, 2014. View at Publisher · View at Google Scholar
  24. R. H. Rao, V. R. McCready, and G. S. Spathis, “Iodine kinetic studies during amiodarone treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 62, no. 3, pp. 563–568, 1986. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Stankiewicz, M. Siekierzyński, and J. Wierzbowska, “Influence of topically apllied iodides on urinary iodine excretion and thyroid function,” Klinika Oczna, vol. 105, no. 3-4, pp. 129–131, 2003 (Polish). View at Google Scholar · View at Scopus
  26. M. Pepe, F. M. Graziano, P. Di Perna, G. Salvati, and G. Reda, “Determination of iodine urinary excretion in cordarone induced hyperthyroidism,” Clinica Terapeutica, vol. 148, no. 1-2, pp. 33–39, 1997 (Italian). View at Google Scholar · View at Scopus
  27. M. F. Erdoğan, S. Güleç, E. Tutar, N. Başkal, and G. Erdoǧan, “A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis,” Thyroid, vol. 13, no. 2, pp. 205–209, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Martino, L. Bartalena, F. Bogazzi, and L. E. Braverman, “The effects of amiodarone on the thyroid,” Endocrine Reviews, vol. 22, no. 2, pp. 240–254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. Brooks, D. A. Pattison, E. P. Teo, S. Price, and R. Gurvitch, “Amiodarone-induced destructive thyroiditis associated with coronary artery vasospasm and recurrent ventricular fibrillation,” European Thyroid Journal, vol. 2, no. 1, pp. 65–67, 2013. View at Google Scholar
  30. S. A. Eskes, E. Endert, E. Fliers et al., “Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 2, pp. 499–506, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Bartalena, W. M. Wiersinga, M. L. Tanda et al., “Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association,” Clinical Endocrinology, vol. 61, no. 4, pp. 494–502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. L. A. Diehl, J. H. Romaldini, H. Graf et al., “Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey,” Clinical Endocrinology, vol. 65, no. 4, pp. 433–438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. M. L. Tanda, E. Piantanida, A. Lai et al., “Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists,” Clinical Endocrinology, vol. 69, no. 5, pp. 812–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Tomisti, G. Materazzi, L. Bartalena et al., “Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction,” Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 10, pp. 3515–3521, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Dickstein, C. Shechner, F. Adawi, J. Kaplan, E. Baron, and S. Ish-Shalom, “Lithium treatment in amiodarone-induced thyrotoxicosis,” The American Journal of Medicine, vol. 102, no. 5, pp. 454–458, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Erbil, D. Tihan, A. Azezli et al., “Severe hyperthyroidism requiring therapeutic plasmapheresis in a patient with hydatidiform mole,” Gynecological Endocrinology, vol. 22, no. 7, pp. 402–404, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Aghini-Lombardi, S. Mariotti, P. V. Fosella et al., “Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole,” Journal of Endocrinological Investigation, vol. 16, no. 10, pp. 823–826, 1993. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Czarnywojtek, R. Czepczynski, M. Ruchala et al., “Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT),” Neuroendocrinology Letters, vol. 30, no. 2, pp. 209–214, 2009. View at Google Scholar · View at Scopus
  39. F. Bogazzi, L. Tomisti, C. Ceccarelli, and E. Martino, “Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note,” Clinical Endocrinology, vol. 72, no. 1, pp. 133–134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Roti, R. Minelli, E. Gardini, L. Bianconi, and L. E. Braverman, “Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone: a possible consequence of a destructive process in the thyroid,” Archives of Internal Medicine, vol. 153, no. 7, pp. 886–892, 1993. View at Publisher · View at Google Scholar · View at Scopus